215917-99-0

Basic information

• Product Name: tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate
• Synonyms: 3(R)-HYDROXYMETHYL-4-BOCMORPHOLINE;tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate;(R)-4-Boc-3-hydroxymethylmorpholine;(R)-tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate;(R)-3-Hydroxymethylmorpholine-4-carboxylic Acid tert-Butyl Ester;4-Morpholinecarboxylic acid, 3-(hydroxymethyl)-, 1,1-dimethylethyl ester, (3R)-;(R)-N-Boc-3-Hydroxymethylmorpholine;(3R)-3-(hydroxymethyl)morpholine-4-carboxylate
• CAS NO: 215917-99-0
• Molecular Formula: C₁₀H₁₉NO₄
• Molecular Weight: 217.26
• Product Categories: pharmacetical;API intermediates;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 215917-99-0.mol

Chemical Properties

• Boiling Point: 320.708 °C at 760 mmHg
• Flash Point: 147.759 °C
• Appearance: /
• Density: 1.118 g/cm³
• Vapor Pressure: 2.53E-05mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: 2-8°C
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate(215917-99-0)
• EPA Substance Registry System: tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate(215917-99-0)

Safety Data

• Hazardous Substances Data: 215917-99-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate is used as an intermediate in the synthesis of BMS-599626, a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. This application is significant because it helps in the development of targeted therapies for various types of cancer, potentially improving patient outcomes and quality of life.
As an intermediate in the pharmaceutical industry, tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate plays a vital role in the creation of new drugs that can address unmet medical needs. Its unique chemical properties allow for the development of innovative drug candidates with improved efficacy, safety, and pharmacokinetic profiles.

InChI:InChI=1/C10H19NO4/c1-10(2,3)15-9(13)11-4-5-14-7-8(11)6-12/h8,12H,4-7H2,1-3H3/t8-/m1/s1

Upstream product

• 106973-37-9 (3S)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 
• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 101376-26-5 (3R)-4-benzyl-3-(hydroxymethyl)-morpholine 
• 714971-27-4 (R)-(4-benzylmorpholin-3-yl)methanol hydrochloride 

Downstream Products

• 714971-12-7 (S)-tert-butyl 3-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-ylcarbamoyloxy)methyl)morpholine-4-carboxylate 
• 714971-09-2 [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (3S)-3-morpholinylmethyl ester 
• 1212377-10-0 [(3R)-morpholin-3-yl]methanol hydrochloride 
• 1187929-33-4 tert-butyl (3R)-3-(aminomethyl)morpholine-4-carboxylate 
• 218594-01-5 (S)-3-formylmorpholin-4-carboxylic acid tert-butyl ester 
• 1357576-06-7 4-((R)-4-((S)-3-((tert-butyldiphenylsilyloxy)methyl)morpholino)-4-oxo-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide 
• 1357576-05-6 (S)-3-((tert-butyldiphenylsilyloxy)methyl)morpholine hydrochloride 
• 1357576-04-5 (S)-tert-butyl 3-((tert-butyldiphenylsilyloxy)methyl)morpholine-4-carboxylate 
• 1159598-84-1 (3R)-3-[4-(4-fluorophenyl)-piperazine-1-carbonyloxymethyl]-morpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

DIHYDROPYRIMIDINYLTHIAZOLE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.

Chiral 3 - morpholine methyl alcohol and 3 - morpholine a acid preparation method of the compound

The invention discloses a novel method for preparing chiral 3-morpholine methanol and 3-morpholine formic acid compounds. The method comprises the following steps: taking chiral serine as an initial material to obtain a serine ester (III) from a catalyst by esterification; reacting with halogen acetyl halide under an alkaline condition to obtain a compound (IV); obtaining a compound (V) by hydroxyl protection; adding a reducing agent to restore the ester into alcohol (VI); carrying out cyclization under the alkaline condition to obtain a compound (VII); obtaining a target product chiral 3-morpholine methanol compound (I) by amide reduction, hydroxyl deprotection and N protection; obtaining a chiral 3-morpholine formic acid compound (II) by oxidation. The method has the advantages of being low in cost, friendly to environment, simple to operate, high in yield, high in product purity and the like, the used reagent is simple and safe, and an intermediate in the reaction of each step does not need to be further purified, so that the experiment operation is greatly simplified, the production cost is reduced, and the method is applicable to industrial production.

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H- indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epide

Structure-activity relationships in a series of 4-[1H-indazol-5-ylamino] pyrrolo[2,1-f][1,2,4]triazine-6-carbamates identified dual human epidermal growth factor receptor (HER)1/HER2 kinase inhibitors with excellent biochemical potency and kinase selectiv

SYNTHETIC PROCESS

The present invention provides a process for preparing compounds of formula (I) ["insert chemical structure here"](I)or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.